Articles

Articles | October 28, 2020

How anonymization can enrich every stage of the drug development lifecycle

I wrote in our September newsletter about how trial sponsors are well advised to view transparency as much more than just a box that has to be checked off. This time, I would like to dig deeper into ...

Articles | June 10, 2020

A Passion for Excellence

When I think about what passion looks like at Privacy Analytics, it’s a quiet, underlying drive to innovate and push for a better world. If there’s one thing that unifies our team’s diverse set of ...

Articles | April 15, 2020

Putting Our Passion into Action Against COVID-19

Privacy Analytics is wholly committed to the global effort to respond to COVID-19. We have the collective will, the personal urgency and the technical ability to make a meaningful difference in the ...

Articles | November 21, 2019

Can You Comply Your Way to Greatness?

I recently heard something that stuck with me: “Nobody complies their way to greatness.” An interesting comment, and a relevant one for all of us in the clinical trial transparency domain. But is ...

Articles | September 26, 2019

When to Integrate Anonymization of Documents and Data

Should sponsors integrate risk-based anonymization across both documents and structured individual patient data (S-IPD)?

Articles | June 21, 2019

Early Impact of Health Canada’s New Guidelines

Health Canada has introduced new regulatory guidance for anonymizing clinical study reports. As background, Bill C-17 Protecting Canadians from Unsafe Drugs Act (Vanessa’s Law) was initiated to ...